Related Experiment Video

Updated: May 27, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27

Yohann Bernard1, Nigel Ribeiro, Frédéric Thuaud

  • 1Therapeutic Innovation Laboratory, UMR7200, CNRS/Université de Strasbourg, Illkirch, France.

Plos One
|November 9, 2011
PubMed
Abstract

Insights

Flavaglines show promise in preventing doxorubicin-induced cardiotoxicity. Pretreatment with these natural compounds protected heart cells and reduced mortality in mice, suggesting a potential prophylactic role in cancer therapy.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Doxorubicin is an effective cancer treatment but causes dose-limiting cardiotoxicity.
  • Preventing doxorubicin-induced cardiomyopathy is crucial for patient outcomes.
  • Flavaglines, known for neuroprotection, were investigated for cardioprotective effects.

Purpose of the Study:

  • To investigate the potential of flavaglines to prevent doxorubicin-induced cardiotoxicity.
  • To elucidate the mechanism underlying flavagline-mediated cardioprotection.

Main Methods:

  • In vitro studies using H9c2 cardiomyocytes and doxorubicin.
  • Annexin V, TUNEL, and active caspase-3 assays to assess cell viability.
  • Hsp27 knockdown experiments.
  • In vivo studies in mice treated with flavagline compound FL3.

Main Results:

  • Flavagline pretreatment significantly increased the viability of doxorubicin-injured cardiomyocytes.
  • Phosphorylation of heat shock protein Hsp27 was identified as a key mechanism in flavagline cardioprotection.
  • Hsp27 knockdown abolished the protective effect of flavaglines.
  • FL3 administration in mice reduced cardiomyocyte apoptosis and cardiac fibrosis, decreasing mortality by 50%.

Conclusions:

  • Flavaglines demonstrate significant cardioprotective effects against doxorubicin-induced toxicity.
  • These findings suggest flavaglines have prophylactic potential in mitigating doxorubicin cardiotoxicity.
  • Targeting Hsp27 phosphorylation may be a therapeutic strategy for preventing chemotherapy-induced heart damage.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...